- Home
- SNSE vs RLMD Comparison
SNSE vs RLMD Comparison
Compare SNSE & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- RLMD
- Stock Information
- Founded
- SNSE 2005
- RLMD 2004
- Country
- SNSE United States
- RLMD United States
- Employees
- SNSE N/A
- RLMD N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- SNSE Health Care
- RLMD Health Care
- Exchange
- SNSE Nasdaq
- RLMD Nasdaq
- Market Cap
- SNSE 12.5M
- RLMD 11.5M
- IPO Year
- SNSE 2021
- RLMD N/A
- Fundamental
- Price
- SNSE $0.33
- RLMD $0.28
- Analyst Decision
- SNSE Strong Buy
- RLMD Hold
- Analyst Count
- SNSE 4
- RLMD 4
- Target Price
- SNSE $4.25
- RLMD $4.25
- AVG Volume (30 Days)
- SNSE 8.2M
- RLMD 381.8K
- Earning Date
- SNSE 03-28-2025
- RLMD 03-27-2025
- Dividend Yield
- SNSE N/A
- RLMD N/A
- EPS Growth
- SNSE N/A
- RLMD N/A
- EPS
- SNSE N/A
- RLMD N/A
- Revenue
- SNSE N/A
- RLMD N/A
- Revenue This Year
- SNSE N/A
- RLMD N/A
- Revenue Next Year
- SNSE N/A
- RLMD N/A
- P/E Ratio
- SNSE N/A
- RLMD N/A
- Revenue Growth
- SNSE N/A
- RLMD N/A
- 52 Week Low
- SNSE $0.25
- RLMD $0.24
- 52 Week High
- SNSE $1.94
- RLMD $5.09
- Technical
- Relative Strength Index (RSI)
- SNSE 34.62
- RLMD 42.52
- Support Level
- SNSE $0.25
- RLMD $0.26
- Resistance Level
- SNSE $0.76
- RLMD $0.32
- Average True Range (ATR)
- SNSE 0.07
- RLMD 0.03
- MACD
- SNSE -0.01
- RLMD 0.00
- Stochastic Oscillator
- SNSE 14.76
- RLMD 24.13
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.